Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

The Cannigma

SEPTEMBER 12, 2021

The safety of using these products however, is still unknown. Marijuana (defined in the US as any cannabis plant where THC>0.3%) is a schedule I drug according to the DEA and FDA. Rather, it was based on a policy that was created in the 1950s, before THC or CBD were isolated and before the endocannabinoid system was discovered.

THC 98

THC Research and Development Cannabinoids CBD 98

Cannabis Law Report

MARCH 25, 2019

Both paths are complex processes in which scientific, medical, policy and political forces have influence. There are other avenues Congress can take besides rescheduling marijuana to ameliorate the seeming breakdown in federalism brought about by federal marijuana policy. It was not a policy priority of the Obama administration.

Banking 45

Banking Law Marijuana State Laws 45